heal

A Trio of BioTech Stock’s Showing Strong Performances; VBI Vaccines, Inc. (NASDAQ:VBIV), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), and Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS)

BiotechStocks.com Issues Opinion Report on stocks under 10 dollars making waves in the biotechnology market sector

On Monday morning, U.S. stock markets were on the rise as China increased its effort’s to halt its tumbling economy, and Saudi Arabia continued with its plan to stabilize the oil market. The People’s Bank of China has lowered the reserve requirement ratio for its commercial banks, making the nation more liquid to increase investments. Meanwhile, Saudi Arabia announced that it was continuing to join with other nations to cap their oil production, and aide in oil prices’ rebound. As a result of these determinations, Wall Street opened higher on Monday as the S&P 500 index is on pace to snap its two month run of losses. With the market seemingly on the rise, three biotech companies: VBI Vaccines, Inc. (NASDAQ:VBIV), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), and Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS) are poised to deliver strong value to their respective shareholders.

VBI Vaccines, Inc. (NASDAQ:VBIV)

VBI Vaccines, Inc. is in the business of meeting its customer’s biopharmaceutical needs through the development of products that are targeted at underserved markets, can withstand changing temperatures, and that closely mimic the target virus. In a recent press release, VBI Vaccines, Inc. announced that they have agreed to partner with GlaxoSmithKline Biologicals SA in an effort to enhance their vaccine’s stability. When speaking on the partnership, CEO of VBI Vaccines, Inc., Jeff Baxter said, “With our partners, we seek to develop a next generation of vaccines and biologics with improved stability characteristics that allow for consistently safe and effective administration in both established and emerging markets… We’re thrilled to be working with GlaxoSmithKline, a leading global healthcare company, to explore the potential of the LPV technology to their pipeline. This collaboration further validates the significant potential of our LPV Platform.”

The press release pertaining to VBI Vaccines, Inc.’s partnership was released on February 9th, and the market seemingly took two days to react to the news as their stock remained steady up until the 11th. However, since that time, the market has reacted favorably to the news with VBI Vaccine’s stock, NASDAQ:VBIV, has grown 8.95% since that day. Over that time the stock price has produced an averaged daily return of 1.03%. However, looking closely at the stock price’s movements in that time period shows higher daily returns, with the price rising 11.57% on February 16th. VBI Vaccines, Inc.’s common stock (NASDAQ:VBIV) has proven its ability to produce returns to its shareholders following news pertaining to the company making strides towards reaching its mission through the use of strategic partnerships.

DOWNLOAD A FREE INVESTOR PRESENTATION ON VBIV

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

Ariad Pharmaceuticals, Inc. aims to satisfy their customer’s cancer treatment needs through the development and commercialization of treatments that provide therapy to patients with aggressive cancers, apply to cancer’s in which the current treatment is not satisfactory, and are innovative in nature. In a recent press release, Ariad Pharmaceuticals, Inc. highlighted key information pertaining to their 2015 fourth-quarter financial report. The report displayed that the company’s quarterly sales revenue stemming from the sales of their product Iclusig increased 56% from the same quarter one-year prior. In addition, annual sales revenues from the sales of Iclusig increased 102% from the preceding year. Paris Panayiotopoulos, president and CEO of Ariad Pharmaceuticals, Inc., spoke about the importance of these numbers, ”We had a strong fourth quarter of sales for Iclusig and 102 percent growth year over year… This is a very important year for ARIAD as we work to complete our ongoing review of strategic initiatives to deliver patient and shareholder value. In addition to maximizing top-line growth of Iclusig, a key event this year will be the presentation of pivotal, registration data on brigatinib at ASCO, along with our planned filing for marketing approval of brigatinib in the U.S.”

Prior to the announcement of the release of their quarterly and annual financial reports on February 23rd, investors were seemingly wary of Ariad Pharmaceuticals Inc.’s stock (NASDAQ:ARIA) as the price closed on February 11th at $4.48. However, since the 11th the stock price has steadily risen, closing on the 26th at $5.31, producing a total return over this time of 18.53%. During this time period, the stock price has risen at an average daily rate of 1.76%. More specifically, on the day following the publishing of their financial reports, February 24th, the stock produced a daily return of 5.36%, displaying the market’s favorable reaction to the company’s growing revenues.

Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS)

Amarantus Bioscience Holdings, Inc., is a biotech company that seeks to provide its customer’s treatments that have the potential for orphan status and are designated in the fields of neurology, psychiatry, and ophthalmology. In a recent press release, Amarantus announced that its product Eltoprazine, a treatment for Parkinson’s Disease Levodopa-Induced Dyskinesia, has officially received orphan drug designation from the FDA. The approval comes following the publishing of positive results from a Phase 2 initial proof-of-concept clinical study and the printing of two independent peer-reviewed scientific journals that described the instrument of action that Eltoprazine uses to treat PD LID. With regards to the news, President and CEO of Amarantus, Gerald E. Commissiong, said, “The grant of this orphan drug designation for eltoprazine in PD-LID squarely positions Amarantus as an orphan drug company, as each of our pipeline candidates in our therapeutics division has received such designations from the FDA for one or more indications… PD-LID is a tremendously debilitating disorder, and we will now begin evaluating expedited pathways to market for eltoprazine that may now be afforded by the orphan drug designation.”

In recent weeks, Amarantus Bioscience Holdings, Inc.’s stock (OTCMKTS:AMBS) has proven its ability to provide returns over a short time period. The 13 trading day period between January 20th and February 5th saw Amarantus’ stock rise from the closing price of $0.2195 to $0.33. These closing figures produce a return of 50.34% over the 13 day period. Furthermore, during this period of growth, Amarantus’ stock price rose at an average daily rate of 4.30% with single day returns reaching as high as 27.83% seen on January 22nd.

Recent market trends have seen Wall Street rising due to foreign news. Due in part to China’s efforts to strengthen its national economy, and the announcement from Saudi Arabia that multiple nations are joining together to repair the oil market, domestic equities have been on the rise. VBI Vaccines, Inc. (NASDAQ:VBIV), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), and Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS) have recently delivered increasing value to their shareholders and seek to continue doing so with market conditions becoming more favorable.

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyrıght 2015 traders350.com. All RIGHTS RESERVED.